VRNA awards cashed out at $13.375 per share; ADSs paid $107 each
Rhea-AI Filing Summary
Verona Pharma plc (VRNA) reported insider transactions tied to a Scheme of Arrangement with Merck Sharp & Dohme LLC that became effective on 10/07/2025. At the Effective Time, each ordinary share was paid $13.375 in cash, and each American Depositary Share (ADS) — representing eight ordinary shares — received $107 in cash. As a result, time-based restricted share units (RSUs) automatically vested and converted into cash payments, and share options with exercise prices below the ADS consideration were converted into cash equal to the excess of $107 over the option exercise price. The filing shows dispositions and cash settlements of multiple equity awards and options for the reporting person, with the signature dated 10/08/2025.
Positive
- Cash consideration secured: Each ADS received $107 in cash at the Effective Time
- Automatic vesting benefit: Time-based RSUs fully vested and converted to cash under the Transaction Agreement
- Options monetized: Options with exercise prices below ADS consideration converted into cash equal to the excess of $107 over the exercise price
Negative
- Loss of equity holdings: Reported dispositions and cash settlements resulted in reduced or zero beneficial ownership in multiple award categories
- Potential tax withholding impact: Cash settlements are subject to withholding taxes, which may reduce net proceeds
Insights
Insider equity awards and options were cashed out under the Merck acquisition, yielding fixed cash consideration per ADS.
The Scheme of Arrangement provided $13.375 per ordinary share, or $107 per ADS, and caused immediate vesting and cash settlement of RSUs and certain options as described. Several classes of derivative awards were converted into cash based on the excess of the ADS consideration over exercise prices.
The key dependency is the Effective Time on 10/07/2025; the reported transactions are administrative cash settlements rather than open-market trades. Monitor any subsequent Form 5 or amendment filings for final reporting of residual holdings or tax withholdings within the next few weeks.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Unit | 72,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 384 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 96,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 240,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 64,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 94,112 | $0.00 | -- |
| Exercise | Ordinary Shares | 72,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 72,000 | $0.00 | -- |
Footnotes (1)
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.
